Shared on08 Aug 25Fair value Decreased 19%
Tandem Diabetes Care’s consensus price target has been revised downward as a result of a lower future P/E despite improved net profit margin, with the fair value estimate decreasing from $27.90 to $24.05. What's in the News Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that can result in a discontinuation of insulin delivery, leading to 700 confirmed adverse events and 59 reported injuries (Key Developments, 2025-08-07).
Shared on24 Apr 25Fair value Decreased 2.80%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 3.59%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 34%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Decreased 11%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.